UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):  February 28, 2006

 

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in charter)

 

Delaware

 

000-31923

 

04-3306140

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

84 October Hill Road, Holliston, MA  01746
(Address of Principal Executive Offices)  (Zip Code)

 

(508) 893-8999
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 5.02                                             Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On February 28, 2006, the Board of Directors of Harvard Bioscience, Inc. (the “Company”) appointed George Uveges to serve as a new member of the Board effective as of the day after the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2005 with the Securities and Exchange Commission. Mr. Uveges will serve as a Class III Director with a term expiring in 2006. Mr. Uveges has been appointed to serve on the Audit Committee of the Board effective as of the same day his appointment to the Board is effective.

 

On March 6, 2006, the Company issued a press release regarding the appointment of Mr. Uveges.  The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number

 

Title

 

 

 

99.1

 

Press release of Harvard Bioscience, Inc. issued on March 6, 2006.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HARVARD BIOSCIENCE, INC.

 

 

 

 

Date: March 6, 2006

By:

/s/ Bryce Chicoyne

 

 

 

 

 Bryce Chicoyne

 

 

 Chief Financial Officer

 

3